Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction to bioseparation and new wide pore monolith columns
- New pharmaceutical active compounds
- Large molecules require larger pores
- Molecular weight vs. molecular size
- Monolithic columns (silica based)
- Application: proteomics
- Bi-modual pore structure
- Chromolith® WP 300 pore structure
- Monolithic columns
- New products, advantages and applications
- New product line: Chromolith® WP 300
- Chromolith® WP 300 separation
- 5 peptide separation: various flow rates
- Chromolith® WP 300 RP4 stability
- Stability of short chain columns (1)
- Stability of short chain columns (2)
- Chromolith® WP 300 RP4
- Chromolith® WP 300 Protein A
- Antifoam agents and antibody binding
- Priming of columns?
- Separation of monoclonal antibodies
- Chromolith® WP 300 Protein A stability
- Chromolith® WP 300 Protein A flow rate
- Immobilization
- Chromolith® WP 300 Epoxy
- Immobilization – epoxy method
- Epoxy immobilization - protocol
- Immobilization – Schiff base method
- Schiff base immobilization - protocol
- Immobilization of penicillin acylase
- Penicillin acylase – enzymatic bioreactor
- Immobilization - affinity chromatography
- Chromolith® WP 300 Epoxy immobilization
- Chromolith® WP 300 - product overview
- Conclusion
- Thank you
- Disclaimer
Topics Covered
- HPLC analysis
- Monolithic columns
- Pore structure of monolithic columns
- Advantages and applications of monolithic columns
- Monolithic column modifications
- Immobilization
- The Schiff base method
- Bioreactors
Links
Categories:
External Links
Talk Citation
Machtejevas, E. (2021, August 29). Advantages of using monolithic silica gel columns in the pharma industry: biomolecule separation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/YRMQ8590.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Machtejevas is an employee of Merck KGaA, all used material belongs to Merck KGaA, however, material is presented from scientific point of view, with no commercial goal intended.
Advantages of using monolithic silica gel columns in the pharma industry: biomolecule separation
Published on August 29, 2021
29 min
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Egidijus Machtejevas.
I'm Lead Expert in Chromatography Product
and Portfolio Management at Merck in Darmstadt.
Today, we have a part 2 talk about the advantages of
using monolithic silica gel columns in the pharmaceutical industry.
Our focus topic today is biomolecule separation.
0:23
First of all, I would like to give you a short introduction about the bioseparation
itself and about our new wide pore monolithic column products.
0:34
Today, we have a new era in the pharmaceutical industry.
In the past, some years ago,
like 20 or more years ago,
90 percent of all therapeutics had been small molecules.
However, today's situation is different and we have a very clear focus on therapeutics,
which are large molecules.
These large molecules provide certain advantages,
like a delivery to target cells and tissues,
with less serious side effects.
But in terms of chromatography,
small molecules and large molecules differ quite significantly.
Of course, small molecules are small and large molecules,
they are much more complex and they are big in size.
Last but not least,
they have quite a number of different functionalization on the surface.
1:25
How would the chromatographic material be
different to accommodate these large molecules?
In this case, we have to have larger pores and there is a very simple general rule.
The pore size must be about 10 times bigger than the Stokes radius of
your molecule in order for the big molecule not to feel the size exclusion effect.
Hide